Pulmonary hypertension associated with interstitial lung disease
ROIVRoivantCatalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Mosliciguat in Pulmonary hypertension associated with interstitial lung disease. The expected timing is based on the latest available company guidance and may change.
PHocus trial. Initiate global Ph2 trial imminently. 9/4/25- Received orphan drug designation in Japan. Present study in progress poster at ERS'25 on September 28, 2025. 02/06/26:- PHocus Ph2 enrollment completed; topline data in H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.